Compare RMT & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMT | KURA |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.0M | 841.6M |
| IPO Year | N/A | 2015 |
| Metric | RMT | KURA |
|---|---|---|
| Price | $13.81 | $11.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.56 |
| AVG Volume (30 Days) | 99.6K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 7.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | N/A | $106.37 |
| P/E Ratio | $9.04 | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $8.66 | $5.45 |
| 52 Week High | $13.97 | $12.49 |
| Indicator | RMT | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 65.61 | 72.07 |
| Support Level | $10.32 | $8.80 |
| Resistance Level | $13.97 | $12.41 |
| Average True Range (ATR) | 0.27 | 0.58 |
| MACD | -0.04 | 0.19 |
| Stochastic Oscillator | 88.08 | 92.39 |
Royce Micro-Cap Trust Inc is a diversified closed-end investment company. The company is engaged in investing in micro-cap securities. It invests in the consumer discretionary sector, including diversified consumer services, hotels, household durables, leisure products, and luxury goods. Consumer staples sector, including beverages, food, and staples retailing, food products, and personal products, Energy sector, including energy equipment and services, and oil, gas, and consumable fuels. The company also invests in other sectors, including healthcare, financials, industrials, IT, telecommunications, and materials.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.